BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16435011)

  • 1. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
    Yang H; Eaves C; de Lima M; Lee MS; Champlin RE; McMannis JD; Robinson SN; Niu T; Decker WK; Xing D; Ng J; Li S; Yao X; Eaves AC; Jones R; Andersson BS; Shpall EJ
    Bone Marrow Transplant; 2006 Mar; 37(6):575-82. PubMed ID: 16435011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
    Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
    Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
    Perseghin P; Gambacorti-Passerini C; Tornaghi L; Dassi M; Pioltelli P; Parma M; Colnaghi F; Giudici G; Elli E; Fumagalli M; Ponchio L; Biondi A; Pogliani EM
    Transfusion; 2005 Jul; 45(7):1214-20. PubMed ID: 15987369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
    Maki G; Tam YK; Berkahn L; Klingemann HG
    Bone Marrow Transplant; 2003 Jun; 31(12):1119-25. PubMed ID: 12796791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
    Koh LP; Hwang WY; Chuah CT; Linn YC; Goh YT; Tan CH; Ng HJ; Tan PH
    Bone Marrow Transplant; 2003 Feb; 31(4):305-8. PubMed ID: 12621468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
    Angstreich GR; Matsui W; Huff CA; Vala MS; Barber J; Hawkins AL; Griffin CA; Smith BD; Jones RJ
    Br J Haematol; 2005 Aug; 130(3):373-81. PubMed ID: 16042686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?
    Pulsipher MA
    Pediatr Blood Cancer; 2004 Oct; 43(5):523-33. PubMed ID: 15382266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.
    Holtz M; Forman SJ; Bhatia R
    Cancer Res; 2007 Feb; 67(3):1113-20. PubMed ID: 17283145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X; Saw KM; Eaves A; Eaves C
    J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.
    Janssen JJ; Deenik W; Smolders KG; van Kuijk BJ; Pouwels W; Kelder A; Cornelissen JJ; Schuurhuis GJ; Ossenkoppele GJ
    Leukemia; 2012 May; 26(5):977-84. PubMed ID: 22157734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study.
    Ruiz-Argüelles GJ; Gómez-Almaguer D; Morales-Toquero A; Gutiérrez-Aguirre CH; Vela-Ojeda J; García-Ruiz-Esparza MA; Manzano C; Karduss A; Sumoza A; de-Souza C; Miranda E; Giralt S;
    Bone Marrow Transplant; 2005 Dec; 36(12):1043-7. PubMed ID: 16247424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.
    Woods-Swafford W; Vnencak-Jones CL; Loken MR; Manes B; Frangoul H
    Pediatr Blood Cancer; 2008 Mar; 50(3):639-41. PubMed ID: 16927371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
    Schultheis B; Pasternak G; Hehlmann R
    Folia Biol (Praha); 2000; 46(6):256-63. PubMed ID: 11140859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of BCR/ABL-negative progenitor cells from chronic myeloid leukemia marrow.
    Leemhuis T; Leibowitz D; Cox G; Srour EF; Tricot G; Hoffman R
    Prog Clin Biol Res; 1992; 377():231-7. PubMed ID: 1279706
    [No Abstract]   [Full Text] [Related]  

  • 16. Autologous hematopoietic cell transplantation for chronic myelogenous leukemia.
    Bhatia R; McGlave PB
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):715-32, xi. PubMed ID: 15271402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.
    Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Cottafavi L; Dotti GP; Rizzoli V
    Bone Marrow Transplant; 1994 Sep; 14(3):425-32. PubMed ID: 7994267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purging efficacy of ZnPcH₁-based photodynamic therapy on chronic myeloid leukemia bone marrow.
    Huang H; Chen Y; Chen W; Wu Y
    Int J Lab Hematol; 2011 Oct; 33(5):477-82. PubMed ID: 21457188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures.
    Chávez-González A; Ayala-Sánchez M; Sánchez-Valle E; Ruiz-Sánchez E; Arana-Trejo RM; Vela-Ojeda J; Mayani H
    Leuk Res; 2006 Mar; 30(3):286-95. PubMed ID: 16111748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.